8th Feb 2013 16:38
This announcement replaces the original announcement released on 2 January 2013 at 16.43 (RNS No: 7101U).
One of the Non-Executive Director's interests in Ordinary Shares of GlaxoSmithKline plc, indicated with an asterix (*) below, was incorrectly stated in the announcement made on 2 January 2013.
Save as disclosed above, all other details remain unchanged. The full amended text is shown below.
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc.
On 31 December 2012, the Company's Non-Executive Directors were provisionally allocated the following awards over Ordinary Shares and American Depositary Shares (ADSs) in the Company through the annual reinvestment of dividends paid throughout 2012:
GlaxoSmithKline Non-Executive Directors Automatic Share Award and Elected Share Award - Annual Dividend Reinvestment
Non-Executive Director | No. of Ordinary Shares | Average Price (£) | No. of ADSs | Average Price ($) |
Sir Christopher Gent | 4,610.092 | 13.43 |
|
|
Prof Sir Roy Anderson | 671.657 | 13.43 |
|
|
Dr Stephanie Burns |
|
| 549.830 | 43.39 |
Ms Stacey Cartwright | 67.351 | 13.43 |
|
|
Sir Crispin Davis | 3,835.178 | 13.43 |
|
|
Ms Judy Lewent |
|
| 41.107 | 43.39 |
Sir Deryck Maughan |
|
| 1,460.014 | 43.39 |
Dr Daniel Podolsky |
|
| 971.294 | 43.39 |
Mr Tom de Swaan | 993.381 | 13.43 |
|
|
Sir Robert Wilson | 1,070.610* | 13.43 |
|
|
The Company and the Non-Executive Directors were informed of these allocations on 2 January 2013.
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
V A Whyte
Company Secretary
8 February 2013
Related Shares:
Glaxosmithkline